Vijith Shetty: Osimertinib Could Alter SOC for Stage III EGFR+ NSCLC

Vijith Shetty, Associate Professor and Consultant Medical Oncologist at KS Hegde Medical Academy, shared on LinkedIn:

“Osimertinib Could Alter SOC for Stage III EGFR+  Non Small Cell Lung Cancer (NSCLC).

Osimertinib reduced the risk of progression or death by 84% compared to placebo in EGFR-mutated, unresectable stage III NSCLC.

Median PFS was 39.1 months for osimertinib versus 5.6 months for placebo.

The 12- and 24-month PFS rates for osimertinib were 74% and 65%, respectively, compared to 22% and 13% for placebo.

Osimertinib’s safety profile was consistent with known data, with most adverse effects being manageable and not leading to treatment discontinuation.

These results position osimertinib as the new standard of care post-chemoradiotherapy for patients with EGFR-mutated, locally advanced NSCLC.”

Additional information.
Source: Vijith Shetty/LinkedIn